Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b

L. Kalabay, Elemér Nemesánszky, Antal Csepregi, Mária Pusztay, Károly Dávid, Gábor Horváth, Ervin Ibrányi, L. Telegdy, A. Pár, Adrienn Bíró, B. Fekete, Judith Gervain, M. Horányi, Pál Ribiczey, Mihály Csöndes, Mónika Kleiber, Szilvia Walentin, Z. Prohászka, G. Füst

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Previously we observed elevation of the serum concentration of two acute-phase protein (AFP) complement components (C9 and C1-inhibitor) in patients with chronic hepatitis C who responded (R) to IFN-α therapy, but not in non-responders (NR). In the present study we investigated the effect of high-dose IFN-α therapy on serum concentrations of two positive [orosomucoid (OROSO) and C-reactive protein (CRP)] and two negative [transferrin (TF) and fetuin/α2HS-glycoprotein (AHSG)] AFP in an outpatient setting. We investigated blood samples of 40 patients with chronic hepatitis C at the onset and at the end of a 3-month treatment with high-dose IFN-α2b (5 MIU/day for 6 weeks, followed by 5 MIU t.i.w.) and of 52 healthy individuals. Serum concentrations of OROSO, TF and AHSG were measured by radial immunodiffusion; CRP levels were determined by immunotubridimetry. Compared to controls, patients with chronic hepatitis C had significantly lower OROSO and CRP, and higher AHSG levels. By the end of treatment, OROSO concentration increased in R (P = 0.0054), but not in NR patients. In contrast, TF levels decreased in R (P = 0.0040), but did not change in NR patients. Similarly, in R patients, AHSG levels tended to decrease (P = 0.0942) following IFN-α treatment. We conclude that the acute-phase reaction is suppressed in patients with chronic hepatitis C that may be potentially related to the responsiveness to IFN-α therapy.

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalInternational Immunology
Volume16
Issue number1
DOIs
Publication statusPublished - Jan 2004

Fingerprint

Acute-Phase Proteins
Chronic Hepatitis C
Orosomucoid
Transferrin
C-Reactive Protein
Therapeutics
Complement C9
Serum
Fetuins
Complement C1
Acute-Phase Reaction
Immunodiffusion
Glycoproteins
Outpatients

Keywords

  • Chronic hepatitis C
  • Fetuin/α2HS-glycoprotein
  • IFN-α therapy
  • Orosomucoid
  • Transferrin

ASJC Scopus subject areas

  • Immunology

Cite this

Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b. / Kalabay, L.; Nemesánszky, Elemér; Csepregi, Antal; Pusztay, Mária; Dávid, Károly; Horváth, Gábor; Ibrányi, Ervin; Telegdy, L.; Pár, A.; Bíró, Adrienn; Fekete, B.; Gervain, Judith; Horányi, M.; Ribiczey, Pál; Csöndes, Mihály; Kleiber, Mónika; Walentin, Szilvia; Prohászka, Z.; Füst, G.

In: International Immunology, Vol. 16, No. 1, 01.2004, p. 51-54.

Research output: Contribution to journalArticle

Kalabay, L, Nemesánszky, E, Csepregi, A, Pusztay, M, Dávid, K, Horváth, G, Ibrányi, E, Telegdy, L, Pár, A, Bíró, A, Fekete, B, Gervain, J, Horányi, M, Ribiczey, P, Csöndes, M, Kleiber, M, Walentin, S, Prohászka, Z & Füst, G 2004, 'Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b', International Immunology, vol. 16, no. 1, pp. 51-54. https://doi.org/10.1093/intimm/dxh024
Kalabay, L. ; Nemesánszky, Elemér ; Csepregi, Antal ; Pusztay, Mária ; Dávid, Károly ; Horváth, Gábor ; Ibrányi, Ervin ; Telegdy, L. ; Pár, A. ; Bíró, Adrienn ; Fekete, B. ; Gervain, Judith ; Horányi, M. ; Ribiczey, Pál ; Csöndes, Mihály ; Kleiber, Mónika ; Walentin, Szilvia ; Prohászka, Z. ; Füst, G. / Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b. In: International Immunology. 2004 ; Vol. 16, No. 1. pp. 51-54.
@article{b591ca0eeda94b99bdc976ee9db35a42,
title = "Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b",
abstract = "Previously we observed elevation of the serum concentration of two acute-phase protein (AFP) complement components (C9 and C1-inhibitor) in patients with chronic hepatitis C who responded (R) to IFN-α therapy, but not in non-responders (NR). In the present study we investigated the effect of high-dose IFN-α therapy on serum concentrations of two positive [orosomucoid (OROSO) and C-reactive protein (CRP)] and two negative [transferrin (TF) and fetuin/α2HS-glycoprotein (AHSG)] AFP in an outpatient setting. We investigated blood samples of 40 patients with chronic hepatitis C at the onset and at the end of a 3-month treatment with high-dose IFN-α2b (5 MIU/day for 6 weeks, followed by 5 MIU t.i.w.) and of 52 healthy individuals. Serum concentrations of OROSO, TF and AHSG were measured by radial immunodiffusion; CRP levels were determined by immunotubridimetry. Compared to controls, patients with chronic hepatitis C had significantly lower OROSO and CRP, and higher AHSG levels. By the end of treatment, OROSO concentration increased in R (P = 0.0054), but not in NR patients. In contrast, TF levels decreased in R (P = 0.0040), but did not change in NR patients. Similarly, in R patients, AHSG levels tended to decrease (P = 0.0942) following IFN-α treatment. We conclude that the acute-phase reaction is suppressed in patients with chronic hepatitis C that may be potentially related to the responsiveness to IFN-α therapy.",
keywords = "Chronic hepatitis C, Fetuin/α2HS-glycoprotein, IFN-α therapy, Orosomucoid, Transferrin",
author = "L. Kalabay and Elem{\'e}r Nemes{\'a}nszky and Antal Csepregi and M{\'a}ria Pusztay and K{\'a}roly D{\'a}vid and G{\'a}bor Horv{\'a}th and Ervin Ibr{\'a}nyi and L. Telegdy and A. P{\'a}r and Adrienn B{\'i}r{\'o} and B. Fekete and Judith Gervain and M. Hor{\'a}nyi and P{\'a}l Ribiczey and Mih{\'a}ly Cs{\"o}ndes and M{\'o}nika Kleiber and Szilvia Walentin and Z. Proh{\'a}szka and G. F{\"u}st",
year = "2004",
month = "1",
doi = "10.1093/intimm/dxh024",
language = "English",
volume = "16",
pages = "51--54",
journal = "International Immunology",
issn = "0953-8178",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b

AU - Kalabay, L.

AU - Nemesánszky, Elemér

AU - Csepregi, Antal

AU - Pusztay, Mária

AU - Dávid, Károly

AU - Horváth, Gábor

AU - Ibrányi, Ervin

AU - Telegdy, L.

AU - Pár, A.

AU - Bíró, Adrienn

AU - Fekete, B.

AU - Gervain, Judith

AU - Horányi, M.

AU - Ribiczey, Pál

AU - Csöndes, Mihály

AU - Kleiber, Mónika

AU - Walentin, Szilvia

AU - Prohászka, Z.

AU - Füst, G.

PY - 2004/1

Y1 - 2004/1

N2 - Previously we observed elevation of the serum concentration of two acute-phase protein (AFP) complement components (C9 and C1-inhibitor) in patients with chronic hepatitis C who responded (R) to IFN-α therapy, but not in non-responders (NR). In the present study we investigated the effect of high-dose IFN-α therapy on serum concentrations of two positive [orosomucoid (OROSO) and C-reactive protein (CRP)] and two negative [transferrin (TF) and fetuin/α2HS-glycoprotein (AHSG)] AFP in an outpatient setting. We investigated blood samples of 40 patients with chronic hepatitis C at the onset and at the end of a 3-month treatment with high-dose IFN-α2b (5 MIU/day for 6 weeks, followed by 5 MIU t.i.w.) and of 52 healthy individuals. Serum concentrations of OROSO, TF and AHSG were measured by radial immunodiffusion; CRP levels were determined by immunotubridimetry. Compared to controls, patients with chronic hepatitis C had significantly lower OROSO and CRP, and higher AHSG levels. By the end of treatment, OROSO concentration increased in R (P = 0.0054), but not in NR patients. In contrast, TF levels decreased in R (P = 0.0040), but did not change in NR patients. Similarly, in R patients, AHSG levels tended to decrease (P = 0.0942) following IFN-α treatment. We conclude that the acute-phase reaction is suppressed in patients with chronic hepatitis C that may be potentially related to the responsiveness to IFN-α therapy.

AB - Previously we observed elevation of the serum concentration of two acute-phase protein (AFP) complement components (C9 and C1-inhibitor) in patients with chronic hepatitis C who responded (R) to IFN-α therapy, but not in non-responders (NR). In the present study we investigated the effect of high-dose IFN-α therapy on serum concentrations of two positive [orosomucoid (OROSO) and C-reactive protein (CRP)] and two negative [transferrin (TF) and fetuin/α2HS-glycoprotein (AHSG)] AFP in an outpatient setting. We investigated blood samples of 40 patients with chronic hepatitis C at the onset and at the end of a 3-month treatment with high-dose IFN-α2b (5 MIU/day for 6 weeks, followed by 5 MIU t.i.w.) and of 52 healthy individuals. Serum concentrations of OROSO, TF and AHSG were measured by radial immunodiffusion; CRP levels were determined by immunotubridimetry. Compared to controls, patients with chronic hepatitis C had significantly lower OROSO and CRP, and higher AHSG levels. By the end of treatment, OROSO concentration increased in R (P = 0.0054), but not in NR patients. In contrast, TF levels decreased in R (P = 0.0040), but did not change in NR patients. Similarly, in R patients, AHSG levels tended to decrease (P = 0.0942) following IFN-α treatment. We conclude that the acute-phase reaction is suppressed in patients with chronic hepatitis C that may be potentially related to the responsiveness to IFN-α therapy.

KW - Chronic hepatitis C

KW - Fetuin/α2HS-glycoprotein

KW - IFN-α therapy

KW - Orosomucoid

KW - Transferrin

UR - http://www.scopus.com/inward/record.url?scp=0347359052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347359052&partnerID=8YFLogxK

U2 - 10.1093/intimm/dxh024

DO - 10.1093/intimm/dxh024

M3 - Article

VL - 16

SP - 51

EP - 54

JO - International Immunology

JF - International Immunology

SN - 0953-8178

IS - 1

ER -